Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse MKT  >  ImmunoCellular Therapeutics Ltd    

 SummaryNewsCalendarCompanyFinancialsRevisions 
Financials ($)
More Financials
Company
ImmunoCellular Therapeutics, Ltd. is a clinical-stage company, which engages in the development of immune-based therapies for the treatment of cancers.Its lead product candidate, ICT-107, is a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells. 
Sector
Biotechnology & Medical Research
Calendar
08/23 | 11:00pmSpecial Situation
More about the company
Latest news on IMMUNOCELLULAR THERAPEUTIC
08/17 IMMUNOCELLULAR THERAPEUTICS, LTD. : Change in Directors or Principal Officers (f..
08/17 IMMUNOCELLULAR THERAPEUTICS, LTD. : Results of Operations and Financial Conditio..
08/15 IMMUNOCELLULAR THERAPEUTICS : Announces Second Quarter 2017 Financial Results
08/14 IMMUNOCELLULAR THERAPEUTICS : Management's Discussion and Analysis of Financial ..
07/27 IMMUNOCELLULAR THERAPEUTICS : Announces Pricing of Public Offering of Convertibl..
07/24 IMMUNOCELLULAR THERAPEUTICS, LTD. : Other Events (form 8-K)
07/21 IMMUNOCELLULAR THERAPEUTICS, LTD. : Amendments to Articles of Inc. or Bylaws; Ch..
07/18 IMMUNOCELLULAR THERAPEUTICS : Announces Pricing of Public Offering of Convertibl..
07/06 JUNE 30 DEADLINE : Lundin Law PC Announces a Securities Class Action Lawsuit aga..
07/06 IMMUNOCELLULAR THERAPEUTICS : Receives Notice from NYSE MKT for Noncompliance wi..
More news
Sector news : Biotechnology & Medical Research - NEC
08/17 FDA expands use of AstraZeneca/Merck ovarian cancer drug
08/15 Three CEOs resign from Trump council over Charlottesville
08/14DJHot Stocks to Watch in the U.S. and Canada
08/11DJGILEAD SCIENCES : England's NHS Turns to Clinical Trial to Make Cheaper HIV Drug..
08/11DJGILEAD SCIENCES : England's NHS Turns to Clinical Trial to Make Cheaper HIV Drug..
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
2016 ImmunoCellular Therapeutics' (IMUC) CEO Andrew Gengos on Q3 2016 Results - Ea..
2016 ImmunoCellular Therapeutics EPS in-line
2016 ImmunoCellular Therapeutics' (IMUC) CEO Andrew Gengos on Q2 2016 Results - Ea..
2016 ImmunoCellular Therapeutics beats by $0.01
2016 ImmunoCellular's late-stage study of lead product candidate in glioblastoma c..
Income Statement Evolution
Consensus
 
Mean consensus
Number of Analysts
Average target price -
Spread / Average Target -100%
EPS Revisions
Managers
NameTitle
Anthony J. Gringeri President, Chief Executive Officer & Director
Gary S. Titus Chairman & Secretary
David E. Fractor Chief Financial Officer
John S. Yu Director
Rahul Singhvi Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
IMMUNOCELLULAR THERAPEUTICS LTD5
INCYTE CORPORATION20.86%24 929
QUINTILES IMS HOLDINGS INC20.38%19 823
LONZA GROUP40.29%17 682
CELLTRION, INC.--.--%11 804
ALKERMES PLC-8.38%7 821